Table 1.
Demographics, clinicopathological and serological parameters of study participants.
| Peripheral Blood (PB) | Minor salivary gland (MSG) tissues | |||||||
|---|---|---|---|---|---|---|---|---|
| Disease parameters | Healthy Controls (n=30) |
SS-non lymphoma (n=31) |
SS- lymphoma (n=13) |
p- value1 |
Sicca Controls (n=17) |
SS-non lymphoma (n=31) |
SS- lymphoma (n=10) |
p- value2 |
| Gender/ Female, n (%) | 26/30 (86.7) | 27/31 (87.1) | 12/13 (92.3) | ns | 17/17 (100) | 30/31 (97.8) | 10/10 (100) | ns |
| Mean age (years) (±SD) | 51.9±14. 5 | 54.0±17.2 | 55.8 ±15.1 | ns | 48.0±12.1 | 53.2±13.6 | 53.2±15.7 | ns |
| Disease duration (years) (mean±SD) | na | 7.7±5.4 | 6.3±4.9 | ns | 9.9±1.2 | 8.1±5.9 | 11.9±7.6 | |
| Dry mouth, n (%) | na | 26/31 (83.9) | 13/13 (100) | ns | 15/17 (88.2) | 27/29 (93.1) | 10/10 (100) | |
| Dry eyes, n (%) | na | 27/31 (87.1) | 12/13 (92.3) | ns | 4/17 (23.5) | 26/29 (89.7) | 7/9 (77.8) | ns |
| Shirmer's test positive, n (%) | na | 20/29 (69.0) | 12/12 (100) | 0.03 | na | 22/27 (81.5) | 9/9 (100) | ns |
| Rose Bengal test positive, n (%) | na | 6/18 (33.3) | 6/12 (50.0) | ns | na | 14/23 (60.9) | 6/9 (66.7) | ns |
| Focus score (mean±SD) | na | 1.8±2.5 | 4.4±2.5 | 0.13±0.03 | 2.0±1.1 | 3.4±2.8 | ||
| Tarpley score (mean±SD) | na | 1.2±1.0 | 2.7±0.9 | na | 2.4±1.1 | 3.8±0.4 | ||
| Salivary gland enlargement, n (%) | na | 7/30 (23.3) | 7/13 (53.8) | 0.08 | na | 11/31 (35.5) | 8/10 (80.0) | 0.03 |
| Arthralgia, n (%) | na | 16/31 (51.6) | 7/13 (53.8) | ns | na | 18/29 (68.1) | 3/9 (33.3) | ns |
| Raynaud's, n (%) | na | 9/31 (29.0) | 6/13 (46.2) | ns | na | 7/30 (23.3) | 3/10 (30.0) | ns |
| Palpable purpura, n (%) | na | 7/31 (22.6) | 7/13 (53.8) | 0.07 | na | 5/30 (16.7) | 4/10 (40.0) | ns |
| Lymphadenopathy, n (%) | na | 9/30 (30.0) | 3/13 (23.1) | ns | na | 1/25 (4.0) | 3/10 (30.0) | 0.06 |
| Lung brochocentric disease, n (%) | na | 7/31 (22.6) | 2/13 (15.4) | ns | na | 1/30 (3.3) | 0/10 (0.0) | ns |
| Leucopenia, n (%) | na | 5/31 (16.1) | 2/13 (15.4) | ns | na | 6/31 (19.4) | 3/10 (30.0) | ns |
| Lymphopenia, n (%) | na | 3/31 (9.7) | 5/13 (38.5) | 0.04 | na | 6/31 (19.4) | 2/9 (22.2) | ns |
| Anti-Ro/SSA, n (%) | na | 25/31 (80.6) | 12/13 (92.3) | ns | na | 21/29 (72.4) | 9/10 (90.0) | ns |
| Anti-La/SSB, n (%) | na | 15/28 (53.6) | 8/13 (61.5) | ns | na | 15/29 (51.7) | 6/10 (60.0) | ns |
| Low complement C4, n (%) | na | 18/31 (58.1) | 9/13 (69.2) | ns | na | 14/30 (46.7) | 6/10 (60.0) | ns |
| Hypergammaglobulinemia, n (%) | na | 20/29 (69.0) | 8/13 (61.5) | ns | na | 15/28 (53.6) | 7/10 (70.0) | ns |
| Positive Rheumatoid Factor, n (%) | na | 13/26 (50.0) | 12/13 (92.3) | 0.01 | na | 19/31 (61.3) | 9/10 (90.0) | ns |
| Erythrocyte sedimentation rate (mean±SD) | na | 37.1±28.8 | 45.1±24.6 | ns | na | 42.1±28.4 | 41.7±24.8 | ns |
| Hydroxychloroquine use, n (%) | na | 5/31 (16.1) | 2/13 (15.4) | ns | na | 3/31 (9.7) | 1/10 (10) | ns |
1
p-value: SS-non lymphoma vs SS-lymphoma patients in PB,
2
p-value: SS-non lymphoma vs SS-lymphoma patients in MSG tissues, na: not applicable, ns: not significance, n: number